Treatment-Resistant Mood Disorders

Erscheinungsjahr 2015
ISBN: 978-0-19-870799-8
Verlag: Oxford University Press

Buch, Englisch, 176 Seiten, Print PDF, Format (B × H): 130 mm x 193 mm, Gewicht: 197 g

Treatment-resistant major depression and bipolar disorder are highly prevalent and disabling conditions associated with substantial morbidity and mortality. The assessment and management of refractory patients with mood disorders is a major clinical challenge for mental health providers. Part of the Oxford Psychiatry Library (OPL) series, this pocketbook provides a concise view of the current definitions, assessment and evidence-based management of treatment-resistant mood disorders and reviews novel therapeutic targets for mood disorders, which may enhance the therapeutic armamentarium of clinicians in the near future. The pocketbook serves as a useful guide for mental health practitioners, including psychiatrists, clinical psychologists, trainees, and interested primary care physicians.

Autoren/Hrsg.

Carvalho, André F

McIntyre, Roger S

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Psychiatrie, Sozialpsychiatrie, Suchttherapie

Inhaltsverzeichnis

- 1: Marcelo T. Berlim, Santiago Tovar-Perdomo and Marcelo P. A. Fleck: Treatment-resistant major depressive disorder: Current Definitions, Epidemiology and Assessment

- 2: Chris Abbott and Mauricio Tohen: Treatment-resistant bipolar disorder: current definitions, epidemiology and assessment

- 3: Jelena Vrublevska and Konstantinos N. Fountoulakis: Determinants of Treatment Resistance: Health Systems and Public Policy Implications

- 4: Sheng-Min Wang and Chi-Un Pae: The influence of psychiatric and medical comorbidities in treatment resistance for mood disorders

- 5: Andrew Haddon Kemp, André Russowsky Brunoni and Rodrigo Machado-Vieira: Predictors of treatment response in major depressive disorder

- 6: Benicio N. Frey: Predictors of Treatment Response in Bipolar Disorder: Lessons from Longitudinal Studies

- 7: André F. Carvalho, Thomas N. Hyphantis and Roger S. McIntyre: Evidence-based Pharmacological Approaches for Treatment-Resistant Major Depressive Disorder

- 8: Poon SH and Sim K: Evidence-based pharmacological approaches for treatment-resistant bipolar disorder

- 9: Jenny Guidi and Giovanni A. Fava: Psychosocial management of treatment-resistant mood disorders: current evidence

- 10: Eric Cretaz, Alexandre Duarte Gigante and Beny Lafer: Electroconvulsive therapy for treatment-resistant mood disorders

- 11: André Russowsky Brunoni, Pedro Shiozawa and Felipe Fregni: Novel non-invasive brain stimulation approaches for treatment-resistant mood disorders

- 12: Giacobbe P, Lipsman N, Lozano A and Kennedy SH: Vagus Nerve Stimulation and Deep Brain Stimulation: Implantable Device-Related Neurostimulation for Treatment-Resistant Mood Disorders

- 13: Marcio Gerhardt Soeiro-de-Souza and Rodrigo Machado-Vieira: Novel Therapeutic Targets for Major Depressive Disorder

- 14: Seetal Dodd: Novel therapeutic targets for bipolar disorder

Über Autor(innen)

Professor André F. Carvalho, MD, PhD, Associate Professor of Psychiatry, Psychiatry Research Group, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE Brazil.
; Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. He was named by Thomson Reuters in 2014 as one of "The World's Most Influential Scientific Minds" for publishing the largest number of articles that rank among those most frequently cited by researchers globally during the previous decade. Dr. McIntyre is involved in multiple research endeavours which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.